Clinically Isolated Syndrome (CIS) Market is segmented By Treatment (Systemic Treatments, Primary Therapy, Primary Therapy, Recurrence Therapy, Recurrence Therapy), By Emerging Drugs, (Olvimulogene nanivacirepvec, Rucaparib), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD Billion) for the above-mentioned segments.
Market Size in USD
CAGR6.7%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 6.7% |
Market Concentration | High |
Major Players | NIHON KOHDEN CORPORATION, Koninklijke Philips N.V., GENERAL ELECTRIC COMPANY, Siemens Healthcare Private Limited, Natus Medical Incorporated |
The clinically isolated syndrome (CIS) market is estimated to be valued at USD 16.03 Bn in 2024 and is expected to reach USD 25.19 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6.7% from 2024 to 2031. The market is driven by rising prevalence of multiple sclerosis and growing awareness about early diagnosis and treatment of the CIS condition to delay progression to multiple sclerosis.